{"id":71441,"date":"2026-05-20T11:35:00","date_gmt":"2026-05-20T11:35:00","guid":{"rendered":"https:\/\/medsbase.com\/hmg-peptide\/"},"modified":"2026-05-21T07:14:08","modified_gmt":"2026-05-21T07:14:08","slug":"hmg-peptide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/hmg-peptide\/","title":{"rendered":"HMG (Humaan Menopauzaal Gonadotropine \/ Menotropine) \u2014 Onderzoekskwaliteit"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is HMG (research-grade)?<\/h3>\n

HMG<\/strong> (Human Menopausal Gonadotropin, also known as menotropin<\/strong>; CAS 61489-71-2) is a urinary-derived glycoprotein-hormone preparation containing equal LH and FSH bioactivity (75 IU LH + 75 IU FSH per vial, the standard 1:1 ratio). Purified from the urine of postmenopausal women \u2014 whose pituitary gonadotropin output is naturally elevated by the absence of negative-feedback inhibition \u2014 hMG is the canonical dual LHCGR + FSHR agonist<\/strong> in endocrine pharmacology and the reference research tool for protocols that need simultaneous Leydig-cell \/ theca-cell steroidogenesis (LH side) and Sertoli-cell \/ granulosa-cell action (FSH side). The supplied research-grade material is the urinary-extracted glycoform at \u226599% HPLC purity. For laboratory research use only.<\/em> Distinct from clinical menotropin preparations (Menopur, Menogon, Repronex).<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Lyophilized \u226599% HPLC-verified urinary-extracted hMG \u00b7 COA available on request \u00b7 Discreet temperature-stable packaging \u00b7 Worldwide research-supply courier \u00b7 1,400+ verified klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
Compound Class<\/strong><\/td>\nGlycoprotein-hormone preparation \u2014 fixed 1:1 mixture of LH and FSH bioactivity; dual LH\/CG-receptor (LHCGR) + FSH-receptor (FSHR) agonist; peptide hormone preparation<\/td>\n<\/tr>\n
Chemical Name<\/strong><\/td>\nHuman Menopausal Gonadotropin (Menotropin; urinary-extracted preparation; synonyms: hMG, urofollitropin-with-LH, gonadotropin menopausal)<\/td>\n<\/tr>\n
CAS-nummer<\/strong><\/td>\n61489-71-2 (menotropin \/ hMG mixed preparation)<\/td>\n<\/tr>\n
Active Components<\/strong><\/td>\nLH<\/strong> (luteinising hormone, ~30 kDa heterodimer; \u03b1 92 aa + \u03b2 121 aa, glycosylated) \u2014 75 IU per vial; FSH<\/strong> (follicle-stimulating hormone, ~30 kDa heterodimer; \u03b1 92 aa + \u03b2 111 aa, glycosylated) \u2014 75 IU per vial. The \u03b1-subunit is shared between LH, FSH, HCG and TSH; the \u03b2-subunits confer receptor specificity. Both gonadotropins are extensively N- and O-glycosylated.<\/td>\n<\/tr>\n
Bioactivity Ratio<\/strong><\/td>\nLH:FSH activity = 1:1 (the standard hMG ratio since potency standardisation in the late-1990s; both activities measured by WHO bioassay against international reference standards)<\/td>\n<\/tr>\n
HCG Co-Purification (research-relevant)<\/strong><\/td>\nA characteristic of urinary-derived hMG preparations: published compositional analyses report that approximately 95% of the in-vivo LH-receptor-mediated bioactivity is attributable to trace HCG co-purified from postmenopausal urine<\/strong> (Wolfenson et\u00a0al. 2005 and others). HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h half-life vs LH’s ~20 min \u2014 so even small HCG amounts dominate the in-vivo LH-equivalent signal. Researchers should be aware of this when comparing hMG to pure recombinant LH (Luveris) preparations.<\/td>\n<\/tr>\n
Werkingsmechanisme<\/strong><\/td>\nDual GPCR agonism. LHCGR<\/strong> (Gs-coupled, Leydig \/ theca \/ granulosa \/ corpus-luteum cells) \u2192 cAMP-PKA-StAR-CYP17A1 cascade \u2192 androgen biosynthesis. FSHR<\/strong> (Gs-coupled, Sertoli cells in males \/ granulosa cells in females) \u2192 cAMP-PKA-CYP19A1\/aromatase cascade \u2192 spermatogenesis support (male) or androgen-to-oestrogen conversion + follicular maturation (female). The dual activation is what distinguishes hMG from pure-LH (Luveris \/ rLH) or pure-FSH (Gonal-F \/ Puregon \/ rFSH) preparations.<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nMixed preparation \u2014 both LH and FSH are heterodimeric glycoproteins. \u03b1-subunit (shared) ~92 aa, identical across LH\/FSH\/HCG\/TSH. LH \u03b2-subunit ~121 aa, FSH \u03b2-subunit ~111 aa. Full sequences available from UniProt: LH\u03b2 (P01229), FSH\u03b2 (P01225), GPH\u03b1 (P01215).<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nMixed urinary-extracted glycoprotein preparation \u2014 FSH (\u03b1 92aa + \u03b2 111aa) + LH (\u03b1 92aa + \u03b2 121aa) heterodimers in ~1:1 bioactivity ratio. No single molecular formula due to heterogeneous glycosylation pattern across the preparation.<\/td>\n<\/tr>\n
Plasma Half-Life<\/strong><\/td>\nFSH activity: terminal half-life ~30\u201340 h (sialylation-driven, similar to other glycoprotein hormones). LH activity in hMG: nominally ~10\u201320 h (but in practice driven by the co-purified HCG fraction with 33\u201337 h half-life \u2014 see HCG co-purification note above).<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyophilized white-to-off-white amorphous powder with mannitol or lactose stabilising matrix; single-use research vials<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC verified); WHO bioassay confirms LH and FSH activity at the labelled 75 IU each. COA available on request.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nReconstitute in bacteriostatic water at 1.0 mL per vial \u2192 75 IU LH + 75 IU FSH per mL working stock; other dilutions per protocol. Cake dissolves rapidly with gentle swirling. Do not shake; do not vortex<\/strong> \u2014 high-shear mixing dissociates the \u03b1\/\u03b2 heterodimers of both LH and FSH components.<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyophilized: 2\u20138 \u00b0C unopened for short-term working stock; \u221220 \u00b0C for long-term storage (stable \u226536 months at \u221220 \u00b0C; \u226518 months at 2\u20138 \u00b0C). Reconstituted: 2\u20138 \u00b0C, use within ~30 days. Protect from light. Do not freeze reconstituted material<\/strong> \u2014 freeze-thaw cycles dissociate the LH and FSH \u03b1\/\u03b2 heterodimers and destroy bioactivity.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nFor laboratory research use only. Not for human or veterinary diagnostic or therapeutic use. hMG \/ menotropin is on the World Anti-Doping Agency (WADA) Prohibited List (class S2, Peptide Hormones, Growth Factors and Related Substances) and is prohibited at all times in male athletes. Researchers in human-subject contexts should be aware of this regulatory status.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is HMG (Menotropin)?<\/h2>\n

HMG<\/strong> \u2014 Human Menopausal Gonadotropin, also known as menotropin<\/strong> (CAS 61489-71-2) \u2014 is a urinary-derived glycoprotein-hormone preparation containing equal amounts of LH (luteinising hormone) and FSH (follicle-stimulating hormone) bioactivity, standardised at 75 IU of each per vial. It is purified by ion-exchange and gel-filtration chromatography from the pooled urine of postmenopausal women, who have naturally elevated pituitary gonadotropin output (LH and FSH typically 50\u2013100+ mIU\/mL each) due to the loss of ovarian negative-feedback inhibition that accompanies menopause.<\/p>\n

The “menopausal” in the name refers to this source: postmenopausal urine is the most concentrated natural source of LH and FSH available for industrial-scale purification, and hMG has been produced from this source since the early 1960s (the original Cesare Serono-developed Pergonal preparation). The compositional refinement of hMG has evolved substantially over the decades \u2014 earlier preparations had highly variable LH:FSH ratios and significant protein-impurity loads; modern preparations (the basis of our research-grade material) are standardised at 75:75 IU bioactivity per vial with \u226599% HPLC purity.<\/p>\n

hMG is the canonical dual-gonadotropin pharmacological tool. Where HCG selectively activates the LHCGR, where pure-LH (recombinant Luveris) selectively activates the LHCGR at physiological half-life, where pure-FSH (recombinant Gonal-F \/ Puregon) selectively activates the FSHR, hMG activates both receptors simultaneously at a fixed 1:1 ratio. The two receptors are expressed on different cell populations within the gonad \u2014 LHCGR on Leydig cells \/ theca cells \/ luteinised granulosa \/ corpus luteum; FSHR on Sertoli cells \/ mural granulosa \u2014 so dual activation produces a complete physiological gonadotropin stimulus that more closely mimics endogenous mid-cycle pituitary output than either receptor activated alone.<\/p>\n

A research-relevant nuance: HCG co-purification.<\/strong> Published compositional analyses of urinary-derived hMG preparations report that the bulk of the in-vivo LH-receptor bioactivity is actually attributable to trace HCG co-purified from postmenopausal urine \u2014 approximately 95% of LH-receptor-mediated bioactivity by some analyses (Wolfenson et\u00a0al., 2005). This is because HCG and LH bind the same LHCGR with similar affinity, but HCG has 33\u201337 h plasma half-life versus LH’s ~20 min, so even small HCG amounts dominate the cumulative in-vivo LH-equivalent signal. This is part of why hMG produces sustained Leydig-cell stimulation despite the nominal “LH activity” of LH itself being short-lived. For research protocols where this distinction matters (pure-LH pharmacology vs HCG-contaminated mixed-LH signal), recombinant LH (Luveris) is the cleaner tool; for protocols where dual LHCGR + FSHR activation at physiological 1:1 ratio is the goal, hMG is the canonical reference.<\/p>\n

Mechanism of Action \u2014 Dual LHCGR + FSHR Activation<\/h2>\n

hMG’s mechanism is the dual sum of its two component activities, both well-characterised in endocrine pharmacology:<\/p>\n